checkAd

     113  0 Kommentare Spectral Receives UKCA Authorization for Burn Indication Expected Commercialization 2nd Half 2024

    DALLAS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that its predictive software DeepView AI-Burn has obtained the final stage of UK Conformity Assessed (UKCA) authorization, for aiding in burn wound diagnosis in the United Kingdom.

    "I am delighted to announce this achievement in our Company’s evolution. The completion of this milestone will allow us to sell our DeepView System in the UK and we expect to swiftly deploy six devices in the UK for customer evaluation and to begin generating revenue in the second half of this year.” said Wensheng Fan, the Company’s Chief Executive Officer. “In addition, this regulatory authorization opens up the ability to expand partnerships with regions such as the Middle East that recognize the UKCA authorization.”   Revenue from commercialization in the UK in 2024 represents an addition to the $28 million revenue guidance previously communicated by the Company.

    The DeepView System wound imaging device uses AI-enabled algorithms analyzing real-life patient wounds that assess clinically validated data points to distinguish between healthy and damaged tissue within seconds, unlike the current standard of care, which requires up to three to four weeks of evaluation. The technology establishes a high level of accuracy, 92%, in discerning whether tissue will heal naturally or necessitate surgical intervention, a process that is currently done by clinicians relying on visual observation and resulting in clinical judgement between only 50% to 75% accuracy.

    “The current practice of prolonged and expensive observation with open wounds that risk infection before deciding on the best management of care is outdated,” said Prof. Paul Chadwick, Spectral AI’s Executive Vice President of the Company’s United Kingdom subsidiary. “This protracted decision process burdens the patient as well as the healthcare system with unnecessary hospitalization time. The authorization of the DeepView System could effectively obviate the need for these long observation periods, accelerating the way we manage burn wounds in the UK.”

    Seite 1 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Spectral Receives UKCA Authorization for Burn Indication Expected Commercialization 2nd Half 2024 DALLAS, Feb. 22, 2024 (GLOBE NEWSWIRE) - Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, …

    Schreibe Deinen Kommentar

    Disclaimer